Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Синдром раздраженного кишечника в Российской Федерации – результаты многоцентрового наблюдательного исследования ROMERUS
Синдром раздраженного кишечника в Российской Федерации – результаты многоцентрового наблюдательного исследования ROMERUS
Маев И.В., Охлобыстина О.З., Халиф И.Л., Андреев Д.Н. Синдром раздраженного кишечника в Российской Федерации – результаты многоцентрового наблюдательного исследования ROMERUS. Терапевтический архив. 2023;95(1):38–51. DOI: 10.26442/00403660.2023.01.202043
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/00403660.2023.01.202043
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
DOI: 10.26442/00403660.2023.01.202043
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обоснование. Cиндром раздраженного кишечника (СРК) – одно из наиболее часто встречающихся функциональных расстройств желудочно-кишечного тракта. Согласно российским рекомендациям для установки диагноза СРК необходимо выполнить стандартное обследование, включающее лабораторные и инструментальные методы оценки, в том числе колоноскопию.
Цель. Описать российскую популяцию пациентов с СРК.
Материалы и методы. Многоцентровое наблюдательное проспективное исследование ROMERUS проводили в 35 клинических центрах в Российской Федерации. В исследование включали пациентов мужского и женского пола в возрасте от 18 до 50 лет с диагнозом СРК, установленным на основании Римских критериев IV, при отсутствии указаний на органическое заболевание желудочно-кишечного тракта. Длительность наблюдения составляла 6 мес, во время которых пациент трижды посещал исследовательский центр. В ходе исследования выполняли сбор данных о демографических и клинических характеристиках пациентов, ранее установленных диагнозах и получаемой лекарственной терапии. Вторичными параметрами стали оценка доли пациентов с диагнозом СРК, подтвержденным стандартным обследованием, среди всех пациентов, удовлетворяющих Римским критериям IV, оценка динамики симптомов СРК, качества жизни (КЖ) и приверженности терапии. Описание характеристик популяции выполняли с помощью методов описательной статистики. Результаты стандартного обследования представляли как процент пациентов с СРК, подтвержденным стандартным обследованием, среди всех пациентов, удовлетворяющих Римским критериям IV, с построением двустороннего 95% доверительного интервала.
Результаты. В исследование включили 1004 пациентов с диагнозом СРК, установленным в соответствии с Римскими критериями IV, в финальный анализ вошли данные 790 (78,7%) пациентов. Средний возраст пациентов составлял 34,0±7,5 года, преобладали пациенты женского пола (70,4%), европеоидной расы (99,4%), состоящие в браке (55,1%), городские жители (97,5%) с высшим образованием (64,5%), имеющие постоянное место работы (74,9%). Для пациентов, включенных в исследование, характерны низкая физическая активность и отсутствие рационального питания. Частота курения составляла 26,3%. У 28,1% пациентов наблюдались симптомы СРК с преобладанием запора, у 28,9% – СРК с преобладанием диареи, у 11,9% – CРК смешанного типа и у 31,1% – неклассифицируемого типа СРК. Основные симптомы СРК – боль (99,7%), вздутие живота (71,1%) и чувство распирания (36,8%). Из сопутствующих заболеваний с наибольшей частотой регистрировали дисфункцию желчевыводящих путей (18,9%) и гастрит (17,2%). До включения в исследование лекарственную терапию получали 28% пациентов. Во время исследования самым часто назначаемым препаратом стал мебеверин (54,1%). За 6 мес наблюдения наблюдалось статистически значимое снижение частоты жалоб на боль, вздутие и распирание живота, а в подгруппах пациентов с СРК с преобладанием запора и СРК с преобладанием диареи – двукратное снижение частоты запора и диареи соответственно. Общая оценка КЖ, измеренная с помощью опросника СРК-КЖ, за время исследования увеличилась с 83,0 до 95,2 балла (p<0,05). При общей оценке своего состояния 69,6% пациентов отметили отсутствие симптомов и 25,3% – выраженное улучшение, по шкале общей оценки состояния пациента врачом у 35% пациентов отсутствовали симптомы и у 51,8% наблюдалось выраженное улучшение.
Заключение. В ходе исследования получены характеристики пациентов с СРК в РФ. Диагноз СРК, установленный в соответствии с Римскими диагностическими критериями IV, подтвержден результатами стандартного обследования у 96,3% пациентов. Использование Римских критериев IV для диагностики СРК позволяет установить диагноз с вероятностью 94,7%. На протяжении 6 мес наблюдения отмечалось клиническое улучшение состояния пациентов, характеризующееся уменьшением тяжести симптомов и улучшением КЖ.
Ключевые слова: синдром раздраженного кишечника, Римские критерии IV, мебеверин
Aim. To characterize the Russian population of IBS patients.
Materials and methods. A multicenter observational prospective study ROMERUS was conducted at 35 clinical centers in the Russian Federation. The study included male and female patients aged 18 to 50 with a diagnosis of IBS based on the Rome IV criteria, with no signs of structural gastrointestinal disease. The follow-up duration was 6 months and included three patients' visits to the study site. During the study, data were collected on patients' demographic and clinical characteristics, medical history, and drug therapy. The secondary parameters included the assessment of the proportion of patients with a diagnosis of IBS confirmed by a standard examination among all patients meeting the Rome IV criteria, the evaluation of the change over time of the IBS symptoms, quality of life (QoL), and adherence to therapy. Characterization of the population was performed using descriptive statistics methods. The standard examination results were presented as the percentage of patients with IBS confirmed by the standard examination among all patients meeting the Rome IV criteria, with a two-sided 95% confidence interval.
Results. The study included 1004 patients with a diagnosis of IBS according to the Rome IV criteria, with 790 (78.7%) patients included in the final analysis. The mean age of patients was 34.0±7.5 years; they were predominantly female (70.4%), Caucasian (99.4%), married (55.1%), urban residents (97.5%) with higher education (64.5%) and a permanent position (74.9%). Patients enrolled in the study have low physical activity and lack a healthy diet. The smoking rate was 26.3%. IBS symptoms with predominant constipation (IBS-C) were observed in 28.1% of patients; 28.9% had IBS with predominant diarrhea (IBS-D), 11.9% had mixed-type IBS, and 31.1% had non-classified IBS. The main IBS symptoms were pain (99.7%), abdominal distension (71.1%), and fullness (36.8%). Biliary tract dysfunction (18.9%) and gastritis (17.2%) were the most frequently reported comorbidities. Prior to enrollment, 28% of patients received drug therapy. The most commonly prescribed drug during the study was mebeverine (54.1%). At 6 months of follow-up, there was a significant reduction of abdominal pain, bloating, and distention, and a twofold reduction in the incidence of constipation and diarrhea in the subgroups of patients with IBS-C and IBS-D, respectively. The overall QoL score measured by the IBS-QoL questionnaire increased from 83.0 to 95.2 points (p<0.05) during the study. In the overall assessment of their condition, 69.6% of patients noted no symptoms and 25.3% reported marked improvement, 35% were asymptomatic according to the physician's overall assessment of the patient's condition, and 51.8% showed significant improvement.
Conclusion. IBS patients in the Russian Federation were characterized. The diagnosis of IBS, established following the Rome IV criteria, is confirmed by the results of a standard examination in 96.3% of patients. The Rome IV criteria for the IBS diagnosis make it possible to establish a diagnosis with a probability of 94.7%. For 6 months of follow-up, there was a clinical improvement with a decrease in the severity of symptoms and a QoL improvement.
Keywords: irritable bowel syndrome, Rome IV criteria, mebeverine
Цель. Описать российскую популяцию пациентов с СРК.
Материалы и методы. Многоцентровое наблюдательное проспективное исследование ROMERUS проводили в 35 клинических центрах в Российской Федерации. В исследование включали пациентов мужского и женского пола в возрасте от 18 до 50 лет с диагнозом СРК, установленным на основании Римских критериев IV, при отсутствии указаний на органическое заболевание желудочно-кишечного тракта. Длительность наблюдения составляла 6 мес, во время которых пациент трижды посещал исследовательский центр. В ходе исследования выполняли сбор данных о демографических и клинических характеристиках пациентов, ранее установленных диагнозах и получаемой лекарственной терапии. Вторичными параметрами стали оценка доли пациентов с диагнозом СРК, подтвержденным стандартным обследованием, среди всех пациентов, удовлетворяющих Римским критериям IV, оценка динамики симптомов СРК, качества жизни (КЖ) и приверженности терапии. Описание характеристик популяции выполняли с помощью методов описательной статистики. Результаты стандартного обследования представляли как процент пациентов с СРК, подтвержденным стандартным обследованием, среди всех пациентов, удовлетворяющих Римским критериям IV, с построением двустороннего 95% доверительного интервала.
Результаты. В исследование включили 1004 пациентов с диагнозом СРК, установленным в соответствии с Римскими критериями IV, в финальный анализ вошли данные 790 (78,7%) пациентов. Средний возраст пациентов составлял 34,0±7,5 года, преобладали пациенты женского пола (70,4%), европеоидной расы (99,4%), состоящие в браке (55,1%), городские жители (97,5%) с высшим образованием (64,5%), имеющие постоянное место работы (74,9%). Для пациентов, включенных в исследование, характерны низкая физическая активность и отсутствие рационального питания. Частота курения составляла 26,3%. У 28,1% пациентов наблюдались симптомы СРК с преобладанием запора, у 28,9% – СРК с преобладанием диареи, у 11,9% – CРК смешанного типа и у 31,1% – неклассифицируемого типа СРК. Основные симптомы СРК – боль (99,7%), вздутие живота (71,1%) и чувство распирания (36,8%). Из сопутствующих заболеваний с наибольшей частотой регистрировали дисфункцию желчевыводящих путей (18,9%) и гастрит (17,2%). До включения в исследование лекарственную терапию получали 28% пациентов. Во время исследования самым часто назначаемым препаратом стал мебеверин (54,1%). За 6 мес наблюдения наблюдалось статистически значимое снижение частоты жалоб на боль, вздутие и распирание живота, а в подгруппах пациентов с СРК с преобладанием запора и СРК с преобладанием диареи – двукратное снижение частоты запора и диареи соответственно. Общая оценка КЖ, измеренная с помощью опросника СРК-КЖ, за время исследования увеличилась с 83,0 до 95,2 балла (p<0,05). При общей оценке своего состояния 69,6% пациентов отметили отсутствие симптомов и 25,3% – выраженное улучшение, по шкале общей оценки состояния пациента врачом у 35% пациентов отсутствовали симптомы и у 51,8% наблюдалось выраженное улучшение.
Заключение. В ходе исследования получены характеристики пациентов с СРК в РФ. Диагноз СРК, установленный в соответствии с Римскими диагностическими критериями IV, подтвержден результатами стандартного обследования у 96,3% пациентов. Использование Римских критериев IV для диагностики СРК позволяет установить диагноз с вероятностью 94,7%. На протяжении 6 мес наблюдения отмечалось клиническое улучшение состояния пациентов, характеризующееся уменьшением тяжести симптомов и улучшением КЖ.
Ключевые слова: синдром раздраженного кишечника, Римские критерии IV, мебеверин
________________________________________________
Aim. To characterize the Russian population of IBS patients.
Materials and methods. A multicenter observational prospective study ROMERUS was conducted at 35 clinical centers in the Russian Federation. The study included male and female patients aged 18 to 50 with a diagnosis of IBS based on the Rome IV criteria, with no signs of structural gastrointestinal disease. The follow-up duration was 6 months and included three patients' visits to the study site. During the study, data were collected on patients' demographic and clinical characteristics, medical history, and drug therapy. The secondary parameters included the assessment of the proportion of patients with a diagnosis of IBS confirmed by a standard examination among all patients meeting the Rome IV criteria, the evaluation of the change over time of the IBS symptoms, quality of life (QoL), and adherence to therapy. Characterization of the population was performed using descriptive statistics methods. The standard examination results were presented as the percentage of patients with IBS confirmed by the standard examination among all patients meeting the Rome IV criteria, with a two-sided 95% confidence interval.
Results. The study included 1004 patients with a diagnosis of IBS according to the Rome IV criteria, with 790 (78.7%) patients included in the final analysis. The mean age of patients was 34.0±7.5 years; they were predominantly female (70.4%), Caucasian (99.4%), married (55.1%), urban residents (97.5%) with higher education (64.5%) and a permanent position (74.9%). Patients enrolled in the study have low physical activity and lack a healthy diet. The smoking rate was 26.3%. IBS symptoms with predominant constipation (IBS-C) were observed in 28.1% of patients; 28.9% had IBS with predominant diarrhea (IBS-D), 11.9% had mixed-type IBS, and 31.1% had non-classified IBS. The main IBS symptoms were pain (99.7%), abdominal distension (71.1%), and fullness (36.8%). Biliary tract dysfunction (18.9%) and gastritis (17.2%) were the most frequently reported comorbidities. Prior to enrollment, 28% of patients received drug therapy. The most commonly prescribed drug during the study was mebeverine (54.1%). At 6 months of follow-up, there was a significant reduction of abdominal pain, bloating, and distention, and a twofold reduction in the incidence of constipation and diarrhea in the subgroups of patients with IBS-C and IBS-D, respectively. The overall QoL score measured by the IBS-QoL questionnaire increased from 83.0 to 95.2 points (p<0.05) during the study. In the overall assessment of their condition, 69.6% of patients noted no symptoms and 25.3% reported marked improvement, 35% were asymptomatic according to the physician's overall assessment of the patient's condition, and 51.8% showed significant improvement.
Conclusion. IBS patients in the Russian Federation were characterized. The diagnosis of IBS, established following the Rome IV criteria, is confirmed by the results of a standard examination in 96.3% of patients. The Rome IV criteria for the IBS diagnosis make it possible to establish a diagnosis with a probability of 94.7%. For 6 months of follow-up, there was a clinical improvement with a decrease in the severity of symptoms and a QoL improvement.
Keywords: irritable bowel syndrome, Rome IV criteria, mebeverine
Полный текст
Список литературы
1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. DOI:10.2147/CLEP.S40245
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.e4. DOI:10.1016/j.cgh.2012.02.029
3. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726-11. DOI:10.1016/j.clinthera.2006.10.010
4. Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract. 2004;54:503-7.
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-54. DOI:10.1053/j.gastro.2009.01.015
6. Grodzinsky E, Hallert C, Faresjö T, et al. Could gastrointestinal disorders differ in two close but divergent social environments? Int J Health Geogr. 2012;11:5.
DOI:10.1186/1476-072X-11-5
7. Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 2012;57:2650-7. DOI:10.1007/s10620-012-2319-9
8. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastoenterol. 2014;20(10):2470-81. DOI:10.3748/wjg.v20.i10.2470
9. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
10. Kanazawa M, Endo M, Yamaguchi K, et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil. 2005;17:705-13. DOI:10.1111/j.1365-2982.2005.00691.x
11. Labus JS, Naliboff BD, Berman SM, et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage. 2009;47:952-60. DOI:10.1016/j.neuroimage.2009.05.078
12. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17-26.
13. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407. DOI:10.1053/j.gastro.2016.02.031
14. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848‑58. DOI:10.1038/ajg.2010.47
15. Seifert B, Rubin G, de Wit N, et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis. 2008;40:659-66. DOI:10.1016/j.dld.2008.02.020
16. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
17. Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-65. DOI:10.1038/ajg.2010.55
18. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-93. DOI:10.1053/j.gastro.2011.06.084
19. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-9.
DOI:10.1016/S0002-9270(02)05444-8
20. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:956-62. DOI:10.1016/j.cgh.2012.12.038
21. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300:1793-805. DOI:10.1001/jama.300.15.1793
22. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70. DOI:10.1053/j.gastro.2013.08.048
23. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol. 2017;11:4:281-3. DOI:10.1080/17474124.2017.1292130
24. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76‑93 [Ivashkin VT, Shelygin YuA, Baranskaya YeK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93 (in Russian)]. DOI:10.22416/1382-4376-2017-27-5-76-93
25. Dumitrascu DL, Babin A, Bordin DS, et al. Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. J Gastrointestin Liver Dis. 2020;29(2):247-50. DOI:10.15403/jgld-2407
26. Фофанова Т.В., Агеев Ф.Т., Смирнова М.Д., и др. Отечественный опросник приверженности терапии: апробация и применение в амбулаторной практике. Системные гипертензии. 2014;11(2):13-6 [Fofanova TV, Ageev FT, Smirnova MD, et al. National questionnaire of treatment compliance: testing and application in outpatient practice. Systemic Hypertension. 2014;11(2):13-6 (in Russian)].
27. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000. DOI:10.1038/ajg.2012.131
28. Gwee KA. Irritable bowel syndrome in developing countries: a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317‑24.
DOI:10.1111/j.1365-2982.2005.00627.x
29. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34(2):189-204. DOI:10.1016/j.gtc.2005.02.008
30. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50. DOI:10.1097/MCG.0b013e318189a7f9
31. Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol. 2001;13:1327-32.
32. Guo YB, Zhuang KM, Kuang L, et al. Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study. Gut Liver. 2015;9(5):649-56. DOI:10.5009/gnl13437
33. Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel). 2017;5(2):21. DOI:10.3390/healthcare5020021
34. Miwa H. Life style in persons with functional gastrointestinal disorders: large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24:464-71.e217. DOI:10.1111/j.1365-2982.2011.01872.x
35. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S-50S. DOI:10.1016/S0002-9343(99)00081-9
36. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75(9):907-12. DOI:10.4065/75.9.907
37. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. DOI:10.1053/gast.2001.27995
38. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311-7.
DOI:10.1016/S0002-9270(98)00321-9
39. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
40. Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol. 2003;15:165-72.
41. WGO Practice Guideline – Irritable Bowel Syndrome (IBS). Update September 2015. Available: https://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed: 01.12.2022.
42. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-56. DOI:10.1053/gast.2002.32392
43. von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-6. DOI:10.1007/s10620-018-5343-6
44. Осипенко М.Ф., Бут-Гусаим В.И., Волошина Н.Б., Бикбулатова Е.А. Синдром «перекреста»: синдром раздраженного кишечника и функциональные расстройства билиарного тракта. Сибирский медицинский журнал (Иркутск). 2008;80(5):21-6 [Osipenko MF, But-Gusaim VI, Voloshina NB, Bikbulatova EA. “Overlap syndrome”: irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Siberian Medical Journal (Irkutsk). 2008;80(5):21-6 (in Russian)].
45. McNally MA, Locke GR, Zinsmeister AR, et al. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334-43. DOI:10.1111/j.1365-2036.2008.03715.x
46. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87(12):1658-63. DOI:10.1046/j.1365-2168.2000.01596.x
47. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:997-1005.
DOI:10.1046/j.1365-2036.2003.01499.x
48. Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci. 1995;40(5):1149-56. DOI:10.1007/BF02064214
49. Guliter S, Yilmaz S, Yakaryilmaz F, Keles H. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135(27-8):407-11.
50. Güçlü M, Pourbagher A, Serin E, et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(8):1309-12. DOI:10.1111/j.1440-1746.2006.04136.x
51. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2-26;quiz S27. DOI:10.1038/ajg.2014.187
52. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
53. Boisson J, Coudert Ph, Dupuis J, et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16:289-92.
54. Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J). BioPsychoSoc Med. 2007;1:6. DOI:10.1007/s40261-014-0233-y
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.e4. DOI:10.1016/j.cgh.2012.02.029
3. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726-11. DOI:10.1016/j.clinthera.2006.10.010
4. Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract. 2004;54:503-7.
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-54. DOI:10.1053/j.gastro.2009.01.015
6. Grodzinsky E, Hallert C, Faresjö T, et al. Could gastrointestinal disorders differ in two close but divergent social environments? Int J Health Geogr. 2012;11:5.
DOI:10.1186/1476-072X-11-5
7. Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 2012;57:2650-7. DOI:10.1007/s10620-012-2319-9
8. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastoenterol. 2014;20(10):2470-81. DOI:10.3748/wjg.v20.i10.2470
9. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
10. Kanazawa M, Endo M, Yamaguchi K, et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil. 2005;17:705-13. DOI:10.1111/j.1365-2982.2005.00691.x
11. Labus JS, Naliboff BD, Berman SM, et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage. 2009;47:952-60. DOI:10.1016/j.neuroimage.2009.05.078
12. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17-26.
13. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407. DOI:10.1053/j.gastro.2016.02.031
14. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848‑58. DOI:10.1038/ajg.2010.47
15. Seifert B, Rubin G, de Wit N, et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis. 2008;40:659-66. DOI:10.1016/j.dld.2008.02.020
16. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
17. Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-65. DOI:10.1038/ajg.2010.55
18. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-93. DOI:10.1053/j.gastro.2011.06.084
19. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-9.
DOI:10.1016/S0002-9270(02)05444-8
20. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:956-62. DOI:10.1016/j.cgh.2012.12.038
21. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300:1793-805. DOI:10.1001/jama.300.15.1793
22. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70. DOI:10.1053/j.gastro.2013.08.048
23. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol. 2017;11:4:281-3. DOI:10.1080/17474124.2017.1292130
24. Ivashkin VT, Shelygin YuA, Baranskaya YeK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93 (in Russian). DOI:10.22416/1382-4376-2017-27-5-76-93
25. Dumitrascu DL, Babin A, Bordin DS, et al. Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. J Gastrointestin Liver Dis. 2020;29(2):247-50. DOI:10.15403/jgld-2407
26. Fofanova TV, Ageev FT, Smirnova MD, et al. National questionnaire of treatment compliance: testing and application in outpatient practice. Systemic Hypertension. 2014;11(2):13-6 (in Russian).
27. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000. DOI:10.1038/ajg.2012.131
28. Gwee KA. Irritable bowel syndrome in developing countries: a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317‑24.
DOI:10.1111/j.1365-2982.2005.00627.x
29. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34(2):189-204. DOI:10.1016/j.gtc.2005.02.008
30. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50. DOI:10.1097/MCG.0b013e318189a7f9
31. Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol. 2001;13:1327-32.
32. Guo YB, Zhuang KM, Kuang L, et al. Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study. Gut Liver. 2015;9(5):649-56. DOI:10.5009/gnl13437
33. Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel). 2017;5(2):21. DOI:10.3390/healthcare5020021
34. Miwa H. Life style in persons with functional gastrointestinal disorders: large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24:464-71.e217. DOI:10.1111/j.1365-2982.2011.01872.x
35. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S-50S. DOI:10.1016/S0002-9343(99)00081-9
36. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75(9):907-12. DOI:10.4065/75.9.907
37. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. DOI:10.1053/gast.2001.27995
38. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311-7.
DOI:10.1016/S0002-9270(98)00321-9
39. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
40. Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol. 2003;15:165-72.
41. WGO Practice Guideline – Irritable Bowel Syndrome (IBS). Update September 2015. Available: https://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed: 01.12.2022.
42. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-56. DOI:10.1053/gast.2002.32392
43. von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-6. DOI:10.1007/s10620-018-5343-6
44. Osipenko MF, But-Gusaim VI, Voloshina NB, Bikbulatova EA. “Overlap syndrome”: irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Siberian Medical Journal (Irkutsk). 2008;80(5):21-6 (in Russian).
45. McNally MA, Locke GR, Zinsmeister AR, et al. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334-43. DOI:10.1111/j.1365-2036.2008.03715.x
46. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87(12):1658-63. DOI:10.1046/j.1365-2168.2000.01596.x
47. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:997-1005.
DOI:10.1046/j.1365-2036.2003.01499.x
48. Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci. 1995;40(5):1149-56. DOI:10.1007/BF02064214
49. Guliter S, Yilmaz S, Yakaryilmaz F, Keles H. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135(27-8):407-11.
50. Güçlü M, Pourbagher A, Serin E, et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(8):1309-12. DOI:10.1111/j.1440-1746.2006.04136.x
51. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2-26;quiz S27. DOI:10.1038/ajg.2014.187
52. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
53. Boisson J, Coudert Ph, Dupuis J, et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16:289-92.
54. Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J). BioPsychoSoc Med. 2007;1:6. DOI:10.1007/s40261-014-0233-y
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.e4. DOI:10.1016/j.cgh.2012.02.029
3. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726-11. DOI:10.1016/j.clinthera.2006.10.010
4. Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract. 2004;54:503-7.
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-54. DOI:10.1053/j.gastro.2009.01.015
6. Grodzinsky E, Hallert C, Faresjö T, et al. Could gastrointestinal disorders differ in two close but divergent social environments? Int J Health Geogr. 2012;11:5.
DOI:10.1186/1476-072X-11-5
7. Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 2012;57:2650-7. DOI:10.1007/s10620-012-2319-9
8. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastoenterol. 2014;20(10):2470-81. DOI:10.3748/wjg.v20.i10.2470
9. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
10. Kanazawa M, Endo M, Yamaguchi K, et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil. 2005;17:705-13. DOI:10.1111/j.1365-2982.2005.00691.x
11. Labus JS, Naliboff BD, Berman SM, et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage. 2009;47:952-60. DOI:10.1016/j.neuroimage.2009.05.078
12. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17-26.
13. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407. DOI:10.1053/j.gastro.2016.02.031
14. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848‑58. DOI:10.1038/ajg.2010.47
15. Seifert B, Rubin G, de Wit N, et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis. 2008;40:659-66. DOI:10.1016/j.dld.2008.02.020
16. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
17. Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-65. DOI:10.1038/ajg.2010.55
18. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-93. DOI:10.1053/j.gastro.2011.06.084
19. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-9.
DOI:10.1016/S0002-9270(02)05444-8
20. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:956-62. DOI:10.1016/j.cgh.2012.12.038
21. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300:1793-805. DOI:10.1001/jama.300.15.1793
22. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70. DOI:10.1053/j.gastro.2013.08.048
23. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol. 2017;11:4:281-3. DOI:10.1080/17474124.2017.1292130
24. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76‑93 [Ivashkin VT, Shelygin YuA, Baranskaya YeK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93 (in Russian)]. DOI:10.22416/1382-4376-2017-27-5-76-93
25. Dumitrascu DL, Babin A, Bordin DS, et al. Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. J Gastrointestin Liver Dis. 2020;29(2):247-50. DOI:10.15403/jgld-2407
26. Фофанова Т.В., Агеев Ф.Т., Смирнова М.Д., и др. Отечественный опросник приверженности терапии: апробация и применение в амбулаторной практике. Системные гипертензии. 2014;11(2):13-6 [Fofanova TV, Ageev FT, Smirnova MD, et al. National questionnaire of treatment compliance: testing and application in outpatient practice. Systemic Hypertension. 2014;11(2):13-6 (in Russian)].
27. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000. DOI:10.1038/ajg.2012.131
28. Gwee KA. Irritable bowel syndrome in developing countries: a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317‑24.
DOI:10.1111/j.1365-2982.2005.00627.x
29. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34(2):189-204. DOI:10.1016/j.gtc.2005.02.008
30. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50. DOI:10.1097/MCG.0b013e318189a7f9
31. Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol. 2001;13:1327-32.
32. Guo YB, Zhuang KM, Kuang L, et al. Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study. Gut Liver. 2015;9(5):649-56. DOI:10.5009/gnl13437
33. Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel). 2017;5(2):21. DOI:10.3390/healthcare5020021
34. Miwa H. Life style in persons with functional gastrointestinal disorders: large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24:464-71.e217. DOI:10.1111/j.1365-2982.2011.01872.x
35. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S-50S. DOI:10.1016/S0002-9343(99)00081-9
36. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75(9):907-12. DOI:10.4065/75.9.907
37. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. DOI:10.1053/gast.2001.27995
38. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311-7.
DOI:10.1016/S0002-9270(98)00321-9
39. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
40. Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol. 2003;15:165-72.
41. WGO Practice Guideline – Irritable Bowel Syndrome (IBS). Update September 2015. Available: https://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed: 01.12.2022.
42. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-56. DOI:10.1053/gast.2002.32392
43. von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-6. DOI:10.1007/s10620-018-5343-6
44. Осипенко М.Ф., Бут-Гусаим В.И., Волошина Н.Б., Бикбулатова Е.А. Синдром «перекреста»: синдром раздраженного кишечника и функциональные расстройства билиарного тракта. Сибирский медицинский журнал (Иркутск). 2008;80(5):21-6 [Osipenko MF, But-Gusaim VI, Voloshina NB, Bikbulatova EA. “Overlap syndrome”: irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Siberian Medical Journal (Irkutsk). 2008;80(5):21-6 (in Russian)].
45. McNally MA, Locke GR, Zinsmeister AR, et al. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334-43. DOI:10.1111/j.1365-2036.2008.03715.x
46. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87(12):1658-63. DOI:10.1046/j.1365-2168.2000.01596.x
47. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:997-1005.
DOI:10.1046/j.1365-2036.2003.01499.x
48. Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci. 1995;40(5):1149-56. DOI:10.1007/BF02064214
49. Guliter S, Yilmaz S, Yakaryilmaz F, Keles H. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135(27-8):407-11.
50. Güçlü M, Pourbagher A, Serin E, et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(8):1309-12. DOI:10.1111/j.1440-1746.2006.04136.x
51. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2-26;quiz S27. DOI:10.1038/ajg.2014.187
52. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
53. Boisson J, Coudert Ph, Dupuis J, et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16:289-92.
54. Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J). BioPsychoSoc Med. 2007;1:6. DOI:10.1007/s40261-014-0233-y
________________________________________________
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.e4. DOI:10.1016/j.cgh.2012.02.029
3. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726-11. DOI:10.1016/j.clinthera.2006.10.010
4. Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract. 2004;54:503-7.
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-54. DOI:10.1053/j.gastro.2009.01.015
6. Grodzinsky E, Hallert C, Faresjö T, et al. Could gastrointestinal disorders differ in two close but divergent social environments? Int J Health Geogr. 2012;11:5.
DOI:10.1186/1476-072X-11-5
7. Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 2012;57:2650-7. DOI:10.1007/s10620-012-2319-9
8. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastoenterol. 2014;20(10):2470-81. DOI:10.3748/wjg.v20.i10.2470
9. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
10. Kanazawa M, Endo M, Yamaguchi K, et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil. 2005;17:705-13. DOI:10.1111/j.1365-2982.2005.00691.x
11. Labus JS, Naliboff BD, Berman SM, et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage. 2009;47:952-60. DOI:10.1016/j.neuroimage.2009.05.078
12. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17-26.
13. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407. DOI:10.1053/j.gastro.2016.02.031
14. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848‑58. DOI:10.1038/ajg.2010.47
15. Seifert B, Rubin G, de Wit N, et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis. 2008;40:659-66. DOI:10.1016/j.dld.2008.02.020
16. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
17. Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-65. DOI:10.1038/ajg.2010.55
18. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-93. DOI:10.1053/j.gastro.2011.06.084
19. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-9.
DOI:10.1016/S0002-9270(02)05444-8
20. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:956-62. DOI:10.1016/j.cgh.2012.12.038
21. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300:1793-805. DOI:10.1001/jama.300.15.1793
22. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70. DOI:10.1053/j.gastro.2013.08.048
23. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol. 2017;11:4:281-3. DOI:10.1080/17474124.2017.1292130
24. Ivashkin VT, Shelygin YuA, Baranskaya YeK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93 (in Russian). DOI:10.22416/1382-4376-2017-27-5-76-93
25. Dumitrascu DL, Babin A, Bordin DS, et al. Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. J Gastrointestin Liver Dis. 2020;29(2):247-50. DOI:10.15403/jgld-2407
26. Fofanova TV, Ageev FT, Smirnova MD, et al. National questionnaire of treatment compliance: testing and application in outpatient practice. Systemic Hypertension. 2014;11(2):13-6 (in Russian).
27. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000. DOI:10.1038/ajg.2012.131
28. Gwee KA. Irritable bowel syndrome in developing countries: a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317‑24.
DOI:10.1111/j.1365-2982.2005.00627.x
29. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34(2):189-204. DOI:10.1016/j.gtc.2005.02.008
30. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50. DOI:10.1097/MCG.0b013e318189a7f9
31. Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol. 2001;13:1327-32.
32. Guo YB, Zhuang KM, Kuang L, et al. Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study. Gut Liver. 2015;9(5):649-56. DOI:10.5009/gnl13437
33. Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel). 2017;5(2):21. DOI:10.3390/healthcare5020021
34. Miwa H. Life style in persons with functional gastrointestinal disorders: large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24:464-71.e217. DOI:10.1111/j.1365-2982.2011.01872.x
35. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S-50S. DOI:10.1016/S0002-9343(99)00081-9
36. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75(9):907-12. DOI:10.4065/75.9.907
37. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. DOI:10.1053/gast.2001.27995
38. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311-7.
DOI:10.1016/S0002-9270(98)00321-9
39. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
40. Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol. 2003;15:165-72.
41. WGO Practice Guideline – Irritable Bowel Syndrome (IBS). Update September 2015. Available: https://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed: 01.12.2022.
42. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-56. DOI:10.1053/gast.2002.32392
43. von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-6. DOI:10.1007/s10620-018-5343-6
44. Osipenko MF, But-Gusaim VI, Voloshina NB, Bikbulatova EA. “Overlap syndrome”: irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Siberian Medical Journal (Irkutsk). 2008;80(5):21-6 (in Russian).
45. McNally MA, Locke GR, Zinsmeister AR, et al. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334-43. DOI:10.1111/j.1365-2036.2008.03715.x
46. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87(12):1658-63. DOI:10.1046/j.1365-2168.2000.01596.x
47. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:997-1005.
DOI:10.1046/j.1365-2036.2003.01499.x
48. Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci. 1995;40(5):1149-56. DOI:10.1007/BF02064214
49. Guliter S, Yilmaz S, Yakaryilmaz F, Keles H. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135(27-8):407-11.
50. Güçlü M, Pourbagher A, Serin E, et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(8):1309-12. DOI:10.1111/j.1440-1746.2006.04136.x
51. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2-26;quiz S27. DOI:10.1038/ajg.2014.187
52. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
53. Boisson J, Coudert Ph, Dupuis J, et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16:289-92.
54. Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J). BioPsychoSoc Med. 2007;1:6. DOI:10.1007/s40261-014-0233-y
Авторы
И.В. Маев1, О.З. Охлобыстина2, И.Л. Халиф 3, Д.Н. Андреев1
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3 ФГБУ «Государственный научный центр колопроктологии им. А.Н. Рыжих» Минздрава России, Москва, Россия
*dna-mit8@mail.ru
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3 Ryzikh State Scientific Center for Coloproctology, Moscow, Russia
*dna-mit8@mail.ru
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3 ФГБУ «Государственный научный центр колопроктологии им. А.Н. Рыжих» Минздрава России, Москва, Россия
*dna-mit8@mail.ru
________________________________________________
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3 Ryzikh State Scientific Center for Coloproctology, Moscow, Russia
*dna-mit8@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.